Compositions and methods for diminishing viral infection and inflammation associated with viral infection

1. A pharmaceutical composition comprising a nearly baseless backbone nucleic acid inhibitor;

wherein the inhibitor is about 10 nucleotides to about 30 nucleotides long; and

wherein the nucleotide at the 3′- or 5′-end of the inhibitor comprises a nucleic acid base and the remaining nucleotides in the inhibitor are abasic.

2. The composition of claim 1 , wherein the inhibitor comprises a backbone selected from the group consisting of a DNA backbone, a RNA backbone, and any combinations thereof.

3. The composition of claim 1 , wherein the backbone of the inhibitor comprises at least one linkage selected from the group consisting of phosphorothioate, phosphoroselenate, boranophosphate, borano phosphate ester, hydrogen phosphonate, alkyl or aryl phosphonate, phosphotriester, methylenephosphonate, sulfone, sulfate, ketyl, phosphorodithioate, phosphoroamidate and phosphate ester.

4. The composition of claim 1 , wherein the inhibitor is selected from the group consisting of single-stranded and double-stranded.

5. The composition of claim 1 , wherein the inhibitor is selected from the group consisting of from about 10 to about 15 nucleotides long, from about 15 to about 20 nucleotides long, from about 20 to about 25 nucleotides long, and from about 25 to about 30 nucleotides long.

6. The composition of claim 1 , wherein at least one nucleotide in the inhibitor comprises a modification selected from the group consisting of 2-O′-methyl, 2′-fluorine, 2′-O-methoxyethyl, 2′-O-aminopropyl, 2′-amino, locked nucleotide (LNA) and 2′,4′-ethylene bridged nucleotide.